Keyword: AbbVie

Patients taking GlaxoSmithKline’s anti-BCMA treatment for multiple myeloma had an overall response rate of 60% and median progression-free survival of one year, new phase 1 data show.

AbbVie and Principia are ending an autoimmunity-focused deal, with Principia regaining the rights to the immunoproteasome inhibitor program.

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.

A UCSF team found that Type 1 diabetes starts with "secretory senescence," a process whereby DNA damage causes beta cells to stop working properly.

J&J has joined AbbVie as a partner for Morphic and its small-molecule integrin platform, pledging up to $725 million to the cause.

Under the deal, AbbVie can acquire Teneobio's affiliate TeneoOne, after which it will take over the development and commercialization of the asset.

It feels like there’s a little more than just precipitation in the air at the J.P. Morgan Healthcare Conference this year: a dash of optimism and cash.

AbbVie’s cancer drug Rova-T will cost the company an additional $4 billion in an impairment charge as the woe keeps coming from this ill-fated deal.

Tizona is starting 2019 with a new CEO and a collaboration with AbbVie that has swelled its coffers with a hefty upfront payment.

AbbVie streamlines management team; FDA taps Flatiron exec for oversight post; and PPD beefs up therapeutics team with new leadership.